Navigation Links
Alexza Reports 2011 First Quarter Financial Results and Provides Business Update
Date:5/9/2011

draft post-approval study outline.Following the REMS guidance meeting in April 2011, Alexza believes there is agreement with the FDA on the definition of the potentially "at-risk" patient population.  Additionally, Alexza and the FDA discussed key elements of screening for these "at-risk" patients, noting that no screen is 100% effective, and components to post-dosing risk mitigation in the event an "at-risk" patient receives a dose of AZ-004.  The FDA emphasized that there are two key components for a risk mitigation proposal:  i) adequacy of monitoring, via patient observation, for a period of time relative to the likely occurrence of a respiratory adverse reaction, and ii) availability of rescue medication (e.g., inhaled albuterol) should an adverse reaction occur.  Alexza will address this updated guidance from the FDA in its draft REMS proposal contained within the AZ-004 NDA resubmission.  The FDA indicated that a complete review of the proposed REMS in conjunction with the full clinical review of the resubmitted NDA will be necessary to determine whether the REMS will be acceptable.  The FDA stated it would present the AZ-004 application to an Advisory Committee.  The objective of this Advisory Committee meeting would be to discuss the proposed approach for managing the risks of AZ-004 in relationship to its patient benefits.  Alexza notes that it has not received the official FDA meeting minutes from the REMS guidance meeting.  The summaries in this release may be altered or supplemented by the information contained in the official meeting minutes.  The Company will provide further U.S. regulatory updates on AZ-004 after receipt of the official FDA minutes or other correspondence if there are material developments in such minutes or correspondence.


  • Alexza previously received notice that AZ-004 is eligible for submission of a Marketing Authorization Application (MAA) under t
    '/>"/>


  • SOURCE Alexza Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Alexza to Present at the MDB Bright Lights Conference 2011
    2. Alexza Prices $16.1 Million Registered Direct Offering
    3. Alexza Reports 2010 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
    4. Alexza to Announce 2010 Year-End Financial Results on Tuesday, March 15, 2011
    5. Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
    6. Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
    7. Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
    8. Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
    9. Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
    10. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
    11. Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/20/2015)... DIEGO , April 20, 2015  Halozyme ... company developing novel oncology and drug-delivery therapies, today ... the American Association for Cancer Research (AACR) annual ... results of its randomized Phase 2 study in ... annual meeting of the American Society of Clinical ...
    (Date:4/20/2015)... PALO ALTO, Calif. , April 20, 2015 ... study demonstrate positive trends in the ability of ... slow the progression of amyotrophic lateral sclerosis (ALS, ... over a 6-month treatment period. While NP001,s slowing ... of the study was not statistically significant, clinically ...
    (Date:4/20/2015)...  OpGen, Inc., a molecular testing and bioinformatics ... management team with the appointments of former Foundation ... Krenitsky , M.D. as president, and Timothy ... With more than 15 years ... biotechnology operations, including senior commercial and operational responsibilities ...
    Breaking Medicine Technology:Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 2Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 3Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 4Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 5Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 2Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 3Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 4Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 5OpGen Appoints Industry Veterans Dr. Kevin Krenitsky as President and Timothy Dec as Interim Chief Financial Officer 2OpGen Appoints Industry Veterans Dr. Kevin Krenitsky as President and Timothy Dec as Interim Chief Financial Officer 3OpGen Appoints Industry Veterans Dr. Kevin Krenitsky as President and Timothy Dec as Interim Chief Financial Officer 4
    (Date:4/20/2015)... 2015 “Consumers deserve to know that their ... children’s hair will not put their health at risk,” said ... National Alliance for Hispanic Health, the nation’s leading Hispanic health ... not had authority to ensure cosmetic and personal care products ... had authority to get products off the shelves if they ...
    (Date:4/20/2015)... April 20, 2015 Goodreads is sponsoring ... Insurance: Why It’s Good for You and Your Company ... Zane Pilzer and Rick Lindquist have released a ... Why It’s Good for You and Your Company. The ... health insurance woes - employer-funded individual health insurance. ...
    (Date:4/20/2015)... The normal response from the doctor used to be, ... Especially if the patient sought medical care after the six-hour ... different. So it’s critical the patient’s loved ones or caregiver ... , Not every emergency room physician or neurosurgeon has the ... But, according to Ronald P. Benitez , neurosurgeon and ...
    (Date:4/20/2015)... Early registration is open for the 2nd ... at the start line. Returning to James Kealoha Beach ... to 500 participants (actually there’s only 499 spots since Big ... Now thru April 30, the entry fee is only $150 ... 1st, the fee goes up to $200 and $100, respectively. ...
    (Date:4/20/2015)... Florida Hospital at Connerton Long Term ... from Select Medical, during the annual ceremony hosted at ... Chief Operating Officer, Debi Martoccio, received the Leadership Award ... of six recipients out of 113 hospitals nationwide. The ... for the contributions to the community as well as ...
    Breaking Medicine News(10 mins):Health News:Statement of National Alliance for Hispanic Health on Senate Introduction of Personal Care Products Safety Act 2Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 2Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 3Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 2Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 3Health News:Hilo Triathlon Kicks Up Its Heels A Second Time; Early Bird Registration Available Online Now. 2Health News:Hilo Triathlon Kicks Up Its Heels A Second Time; Early Bird Registration Available Online Now. 3Health News:Florida Hospital at Connerton Long Term Acute Care Earns Awards from Select Medical including the Stu Dinney Humanitarian Award 2Health News:Florida Hospital at Connerton Long Term Acute Care Earns Awards from Select Medical including the Stu Dinney Humanitarian Award 3
    ... , , RALEIGH ... SNN ; LSE: SN) Biologics & Spine is proceeding to ... of DUROLANE(R) Single Injection, Stabilized Hyaluronic Acid. , , ... and their global commercial partner, Smith & Nephew met today with ...
    ... , , , NEW YORK, Aug. ... the beauty industry is the naturals and organic market and HBA Global ... has obtained one of its most well-known innovators and activists to deliver ... the Special Events Hall of the Javits Center in New York. ...
    ... ... , ... 19, 2009 -- As parents across the country check off school items from their shopping ... season -- foot-friendly shoes. Whether on the school bus, in the classroom or on the ...
    ... , , , ELM GROVE, Wis., Aug. ... rgency D e partment Core Measures: A ... Comp i rion Healthcare Solutions to aid Hospital Emergency ... for AMI , CHA and CAP patients. Compliance with JCAHO ...
    ... Alahari, PhD, Associate Professor of Biochemistry and Molecular Biology at ... first time that a tiny piece of RNA appears to ... cancer and identified a gene that appears to inhibit invasive ... 2009 issue of the Journal of Biological Chemistry . ...
    ... for hand-held technologies , WEDNESDAY, Aug. 19 (HealthDay News) ... to smudge easily, but scientists say they have a ... of protective coatings, a finding that may lead to ... key to anti-smudge coatings is perfluoro alkyl ether, a ...
    Cached Medicine News:Health News:Smith & Nephew Takes Single Injection PMA to Next Stage 2Health News:Smith & Nephew Takes Single Injection PMA to Next Stage 3Health News:Smith & Nephew Takes Single Injection PMA to Next Stage 4Health News:Horst M. Rechelbacher To Deliver HBA Global Expo Keynote Address 2Health News:Horst M. Rechelbacher To Deliver HBA Global Expo Keynote Address 3Health News:Give Shoes the '1,2,3 Test' During Back-To-School Shopping 2Health News:Give Shoes the '1,2,3 Test' During Back-To-School Shopping 3Health News:Compirion Hosts Free Webinar on Achieving JCAHO-Compliant Quality Outcomes 2Health News:Compirion Hosts Free Webinar on Achieving JCAHO-Compliant Quality Outcomes 3Health News:LSUHSC research discovers new targets for treatment of invasive breast cancer 2Health News:A Smudge-Free Smart Phone Screen? 2
    Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
    Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
    Low-profile, hand-held instrument....
    Low-profile, hand-held instrument....
    Medicine Products: